Captor Therapeutics Spolka Akcyjna (WSE: CTX)

Market Cap	356.24M
Revenue (ttm)	18.64M
Net Income (ttm)	-46.69M
Shares Out	4.66M
EPS (ttm)	-9.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,096
Open	74.00
Previous Close	76.00
Day's Range	74.00 - 76.40
52-Week Range	59.00 - 114.50
Beta	0.60
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 19, 2024

About CTX

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has various therapeutic molecules in the preclinical stage. The company was incorporated in 2015 and is headquartered in Wroclaw, Poland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 105
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: CTX

Financial Performance

In 2023, CTX's revenue was 13.20 million, an increase of 44.15% compared to the previous year's 9.16 million. Losses were -70.58 million, 96.6% more than in 2022.